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Abstract
Numerous genetic and epigenetic alterations render cancer cells selectively dependent on specific genes and regulatory
pathways, and represent potential vulnerabilities that can be therapeutically exploited. Here we describe an RNA
interference (RNAi)–based synthetic interaction screen to identify genes preferentially required for proliferation of p53-
deficient (p532) human cancer cells. We find that compared to p53-competent (p53+) human cancer cell lines, diverse
p532 human cancer cell lines are preferentially sensitive to loss of the transcription factor ETV1 and the DNA damage kinase
ATR. In p532 cells, RNAi–mediated knockdown of ETV1 or ATR results in decreased expression of the telomerase catalytic
subunit TERT leading to growth arrest, which can be reversed by ectopic TERT expression. Chromatin immunoprecipitation
analysis reveals that ETV1 binds to a region downstream of the TERT transcriptional start-site in p532 but not p53+ cells. We
find that the role of ATR is to phosphorylate and thereby stabilize ETV1. Our collective results identify a regulatory pathway
involving ETV1, ATR, and TERT that is preferentially important for proliferation of diverse p532 cancer cells.
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Introduction
The p53 tumor suppressor (also called TP53; NP_000537.3)
plays a pivotal role in regulating multiple cellular processes
including cell cycle arrest, apoptosis, cell metabolism and
senescence (reviewed in [1]). Activated p53 can either induce cell
cycle arrest and inhibit cell growth or promote cell apoptosis
depending on the type of stress and the cellular context. Mutations
that perturb p53 function, typically in its DNA-binding domain, or
disruptions of the p53 upstream or downstream regulatory
networks, have been found in more than half of all cancer cases
and are present in cancer-prone families with Li-Fraumeni
syndrome (OMIM#151623) (reviewed in [2]). In addition, loss
of p53 function is often associated with increased resistance to
chemotherapy and/or poor survival (see, for example, [3–5]). For
these reasons, the selective molecular targeting of p53-deficient
(p532) tumors has remained one of the most important goals and
challenges of molecular oncology (reviewed in [6]).
One strategy for treating p532 tumors is to reestablish the
growth-inhibitory functions of p53. The feasibility of this approach
is supported by animal studies demonstrating that reactivation of
wild type p53 leads to tumor regression [7–9]. Several experi-
mental strategies have been used to restore p53 activity. For
example, gene therapy involving viral vectors has been used to
reintroduce p53 into p532 tumor cells [10]. Alternatively, for
cancers that retain a wild type p53 gene, small molecule drugs
have been identified that stabilize and activate p53 by interfering
with its negative regulator MDM2 (NP_002383.2) (reviewed in
[11]). Restoration of p53 function in cancers expressing only
mutant p53 is even more challenging. However, small molecules
that refold mutant p53 proteins, and thus reactivate p53 function,
have been described (reviewed in [12]). Some of these approaches
have progressed to clinical trials but to date none have been found
to have clearly demonstrable clinical benefit [13].
An alternative approach to restoration of p53 function would be
to target proteins that are preferentially required for proliferation
or survival of p532 cells. Such targets can, in principle, be
identified by synthetic lethal interaction screens, an idea first
proposed by Hartwell et al. based upon studies in the budding
yeast Saccharomyces cerevisiae [14]. The validity of this approach is
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supported by the realization that cancer cells are highly dependent
upon or ‘‘addicted’’ to specific genes and regulatory pathways,
confirming the existence of cancer cell-selective synthetic interac-
tion targets (reviewed in [15,16]). In addition, an important proof-
of-principle is the demonstration that small molecule inhibitors of
poly (ADP-ribose)-polymerase (NP_001609.2) are synthetically
lethal with loss-of-function mutations in BRCA1 (NP_009225.1),
BRCA2 (NP_000050.2) as well as other components of the
homologous recombination pathway [17–19]. Here we carry out
an RNA interference (RNAi)-based synthetic interaction screen to
identify a regulatory pathway that is preferentially required for
proliferation of p532 cancer cells.
Results
A Genome-Wide Short Hairpin RNA (shRNA)–Based
Synthetic Interaction Screen Identifies Candidate Genes
Preferentially Required for Proliferation of p532 Cells
To identify genes that are preferentially required for the
viability and proliferation of p532 cancer cells, we designed a
synthetic interaction screen, which is summarized in Figure 1A
and briefly described below. The primary screen was carried out
using a well-characterized isogenic pair of human HCT116
colorectal cancer cell lines, one harboring wild type p53 (p53+
HCT116) and the other bearing a homozygous p53 deletion
(p532 HCT116) [20]. For these and all other cell lines used in this
study, the presence or absence of functional p53 was confirmed by
monitoring expression of the p53 target gene, p21 (also called
CDKN1A; NP_510867.1) (Figure S1). A human shRNA library
comprising ,60,000 shRNAs directed against ,27,000 genes [21]
was packaged into lentivirus particles, pooled and used to infect in
parallel the two HCT116 cell lines. Ten days later, genomic DNA
from both cell lines was isolated, and shRNAs were PCR amplified
and subjected to massively parallel sequencing; as a reference, the
starting shRNA population in both cell lines (taken 40 hours post-
infection) was also analyzed.
Statistical analysis of the four shRNA populations identified
shRNAs targeting 103 genes (Table S1) whose abundance was
significantly decreased in p532 HCT116 cells ($4-fold) but not in
p53+ HCT116 cells (#2-fold) at 10 days post-infection relative to
the earlier time point (Figure 1B). Such shRNAs are presumably
synthetic with the p53 deletion, thus rendering p532 cells
harboring these shRNAs inviable or growth impaired, and leading
to their relative under-representation in the p532 HCT116
population.
To validate candidates isolated from the primary screen, each
shRNA was analyzed in an independent colony formation assay.
p53+ and p532 HCT116 cells were infected with a lentivirus
expressing a single candidate shRNA, and 10 days later cells were
puromycin selected, re-plated at low density, and monitored for
colony formation. This secondary screen revealed 11 genes that,
when knocked down, substantially decreased colony formation in
p532 HCT116 cells compared to p53+ HCT116 cells
(Figure 1C). ShRNAs targeting these 11 genes also preferentially
decreased the ability of p532 HCT116 cells to proliferate in
culture (Figure 1D and summarized in Table S2). Quantitative
RT-PCR (qRT-PCR) confirmed in all cases that expression of the
target gene was decreased in the knockdown cell line (Figure
S2A).
To rule out the possibility that growth inhibition was due to an
off-target effect of the shRNAs, for each of the 11 genes we
derived a short interfering RNA (siRNA) whose sequence was
unrelated to the original shRNA used in the experiments
described above. Figure 1E shows that each siRNA also
preferentially decreased proliferation of p532 HCT116 cells
compared to p53+ HCT116 cells. In all cases, qRT-PCR analysis
confirmed that the siRNA decreased expression of the target gene
(Figure S2B).
Two Candidates, ETV1 and ATR, Are Preferentially
Required for Proliferation of Diverse p532 Cell Lines
p532 tumors from both the same and different types of
cancers vary substantially with regard to additional genetic and
epigenetic aberrations [22]. We were therefore interested in
determining whether the 11 genes we identified were also
preferentially required for the growth of other p532 cancer
cells. To address this issue, we first analyzed an isogenic pair of
human RKO colorectal cancer cell lines, one harboring wild type
p53 (p53+ RKO cells) and the other bearing a homozygous p53
deletion (p532 RKO cells) (see Figure S1). ShRNAs to the 11
genes were introduced into the isogenic pair of RKO cell lines
and proliferation was monitored. The results of Figure 2A
indicate that five genes (ATR [NP_001175.2], ETV1
[NP_001156619.1], GFPT2 [NP_005101.1], NT5C3
[NP_001002009.1] and UMPS [NP_000364.1]) were preferen-
tially required for growth of p532 RKO cells compared to p53+
RKO cells. By contrast, knockdown of the other six genes did not
substantially inhibit growth of either p532 or p53+ RKO cells
and were thus not further analyzed.
We next examined these five candidates in an unrelated isogenic
pair of A549 human lung cancer cell lines. In this case, the
parental p53+ A549 cells were rendered p532 by stable
expression of a p53 dominant-negative mutant [23] (see Figure
S1). The results of Figure 2B show that siRNAs against the five
candidate genes (ATR, ETV1, GFPT2, NT5C3 and UMPS)
preferentially inhibited growth of the p532 A549 cell line.
Finally, we analyzed the five candidate genes in a panel of four
human lung cancer cell lines, two of which expressed wild type p53
(A549 and NCI-H460) and two of which were compromised for
p53 function (NCI-H1299, which lacks p53, and NCI-H522,
which expresses a p53 mutant) (see Figure S1). Of the five
candidate genes, knockdown of two, ATR and ETV1, were the
most consistent in preferentially inhibiting proliferation of p532
cell lines (Figure 2C) and were selected for further analysis. ATR
encodes a checkpoint kinase involved in the DNA damage
response [24], and ETV1 encodes a member of the ETS family
of transcription factors [25].
We also tested whether knockdown of ATR and ETV1 would
preferentially inhibit growth of p532 HCT116 tumors in a
Author Summary
The conversion of a normal cell into a cancer cell involves
activating genes that promote cancer growth (oncogenes)
and/or inactivating genes that normally act to inhibit
cancer growth (tumor suppressor genes). The tumor
suppressor gene p53 is the most frequently mutated gene
in human cancers, being inactivated in approximately half
of all tumors. In addition, loss of p53 function is often
associated with increased resistance to chemotherapy
and/or poor survival. For these reasons, the selective
destruction of p53-deficient (p532) tumors has remained
one of the most important goals and challenges of cancer
therapy. One strategy for destroying p532 tumors is to
inactivate genes that are preferentially required for the
growth or survival of p532 cells. Here we carry out a large-
scale genetic screen to identify a cellular pathway that is
preferentially required for growth of p532 cancer cells.
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
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mouse xenograft model. p53+ or p532 HCT116 cells expressing
an shRNA against ATR or ETV1, or a control non-silencing
shRNA, were injected subcutaneously into opposite flanks of the
same nude mouse, and tumor growth was monitored after four
weeks. As expected, the control p532 HCT116 cells formed
larger tumors than their p53+ counterparts (Figure 2D). Notably,
knockdown of ATR or ETV1 markedly inhibited growth of
p532 HCT116 tumors but did not have a significant effect on
growth of p53+ HCT116 tumors.
ETV1 and ATR Are Preferentially Required for TERT
Expression in p532 Cells
We next sought to investigate the basis by which ETV1 and
ATR were preferentially required for growth of p532 cells. A
previous study has shown that ETV1 is a transcriptional activator
of TERT (NP_001180305.1) [26], which encodes the catalytic
subunit of telomerase and has a well-established role in the
maintenance of cellular proliferation [27]. Therefore, in the first
set of experiments we analyzed the effect of depleting ETV1 as
Figure 1. A genome-wide shRNA–based synthetic interaction screen identifies candidate genes preferentially required for
proliferation of p532 cells. (A) Schematic summary of the screen. p53+ and p532 HCT116 cells were infected in parallel with a pooled lentiviral
human shRNA library. The shRNA population was analyzed by massively parallel sequencing at 40 hours and 10 days post-infection (p.i.). (B) Volcano
plot. The horizontal and vertical lines indicate the selection criteria. The red points represent shRNAs diminished $4-fold in p532 HCT116 cells and
#2-fold in p53+ HCT116 cells at 10 days p.i. relative to 40 hours p.i. Blue points represent shRNAs diminished in both p53+ and p532 cells, and black
points represent shRNAs not diminished in either p53+ or p532 cells. (C) Colony formation assay. p53+ and p532 HCT116 cells infected with a
lentivirus expressing individual candidate shRNAs were selected with puromycin and plated in a serial dilution series in 6-well plates. Only one
dilution set is shown. Colonies were fixed and stained with crystal violet. Control refers to the empty lentiviral vector, pGIPZ. (D) Proliferation assay.
p53+ and p532 HCT116 cells infected with a lentivirus expressing each individual candidate shRNA, or as a control a non-silencing (NS) shRNA, were
selected with puromycin and cell proliferation determined by an Alamar Blue fluorescence assay. The results were normalized to that obtained with a
NS shRNA, which was set to 1. Error bars represent SD. (E) Proliferation of p53+ and p532 HCT116 cells transfected with an siRNA directed against an
individual candidate gene, or a control lamin A/C (LMNA) siRNA, was determined by an Alamar Blue fluorescence assay. The results were normalized
to that obtained with the control shRNA, which was set to 1. Error bars represent SD.
doi:10.1371/journal.pgen.1003151.g001
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
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well as ATR on TERT levels. Significantly, RNAi-mediated
knockdown of ETV1 or ATR resulted in a substantial decrease in
TERT protein (Figure 3A) and mRNA (Figure 3B) levels in p532
HCT116 cells but unexpectedly had only a modest effect on
TERT levels in p53+ HCT116 cells. The effect of knockdown of
both ETV1 and ATR in p532 HCT116 cells on cellular
proliferation and TERT levels was similar to that observed with
single knockdowns (Figure S3A). Pharmacological inactivation of
ATR using two different chemical inhibitors, CGK773 [28] and
ETP46464 [29], also resulted in decreased TERT levels in p532
but not p53+ HCT116 cells (Figure 3C). Inhibition of ATR was
confirmed by monitoring phosphorylation of its target substrate,
CHK1 (also known as CHEK1; NP_001107593.1) (Figure S4).
We also monitored senescence induction and performed cell
cycle analysis in cells depleted of ETV1 or ATR. Figure 4A shows
that in both p53+ and p532 HCT116 cells, RNAi-mediated
knockdown of TERT substantially increased the number of cells
that stained positively for senescence-associated b-galactosidase
activity, indicative of senescence induction (see also Figure S5A).
The level of senescence was higher in p53+ HCT116 TERT
knockdown cells than in p532 HCT116 TERT knockdown cells,
as expected, because p53-directed pathways contribute to senes-
cence [1]. Significantly, Figure 4B shows that RNAi-mediated
knockdown of ETV1 or ATR also induced senescence (see also
Figure S5B). However, following knockdown of ETV1 or ATR,
the induction of senescence was much greater in p532 HCT116
cells compared to p53+HCT116 cells (Figure 4B and Figure S5C),
consistent with the difference in TERT levels (see Figure 3A). In
addition, knockdown of TERT increased the percentage of p532
HCT116 cells but not p53+ HCT116 cells in G2/M (Figure 4C
and Figure S6A). Notably, a similar preferential increase in the
percentage of p532 HCT116 cells in G2/M occurred following
knockdown of ETV1 or ATR (Figure 4D and Figure S6B, S6C).
To determine whether decreased TERT levels were responsible
for the preferential growth defect in p532 HCT116 cells depleted
of ETV1 or ATR, we performed a ‘‘rescue’’ experiment.
Proliferation was measured both by an Alamar Blue assay
(Figure 4E) and by quantifying cell number (Figure S7A) following
knockdown of ETV1 or ATR in p53+ and p532 HCT116 cell
lines stably expressing either TERT or, as a control, green
fluorescence protein (GFP) (Figure S7B). The results of Figure 4E
and Figure S7A show that ectopic expression of TERT
counteracted the large decrease in proliferation that occurred
following knockdown of ETV1 or ATR in p532 HCT116 cells, as
well as the modest proliferative decrease following ETV1
knockdown in p53+ HCT116 cells. Thus, the reduced TERT
levels following depletion of ETV1 or ATR can largely explain the
decreased proliferation of p532 HCT116 cells. Consistent with
this conclusion, TERT knockdown had a similar effect on
proliferation of p532 cell lines to that observed following
knockdown of ETV1 or ATR (see Figure S3). Moreover,
knockdown of both ETV1 and TERT, or ATR and TERT,
Figure 2. ETV1 and ATR are preferentially required for proliferation of diverse p532 cell lines. (A) Proliferation of p53+ and p532 RKO
cells expressing an individual candidate shRNA, or as a control a NS shRNA, was determined by an Alamar Blue fluorescence assay. The results were
normalized to that obtained with the NS shRNA, which was set to 1. Error bars represent SD. ShRNAs that preferentially affect the proliferation of
p532 relative to p53+ cell lines are indicated in red. (B) Proliferation of p53+ and p532 A549 cells transfected with a candidate siRNA, or as a control
a LMNA siRNA, was determined by an Alamar Blue fluorescence assay. The results were normalized to that obtained with the LMNA siRNA, which was
set to 1. Error bars represent SD. ShRNAs that preferentially affect the proliferation of p532 relative to p53+ cell lines are indicated in red. (C)
Proliferation of A549, NCI-H460, NCI-H1299 and NCI-H522 cells expressing a candidate shRNA, or as a control an NS shRNA, was determined by an
Alamar Blue fluorescence assay. The results were normalized to that obtained with the NS shRNA, which was set to 1. Error bars represent SD. ShRNAs
that preferentially affect the proliferation of p532 relative to p53+ cell lines are indicated in red. (D) p53+ and p532 HCT116 cells expressing an ATR
or ETV1 shRNAs or as a control a NS shRNA, were subcutaneously injected into opposite flanks of the same nude mouse, and tumor volume was
measured after 4 weeks. The results were normalized to that obtained in p53+ cells expressing a NS shRNA, which was set to 1. Error bars represent
SD. * P#0.0001.
doi:10.1371/journal.pgen.1003151.g002
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
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decreased proliferation of p532 cell lines similarly to that observed
with single knockdowns (Figure S3).
ATR Interacts with and Phosphorylates ETV1
As described above, ETV1 has been previously shown to
transcriptionally stimulate TERT expression [26]. However, the
basis by which ATR promotes TERT expression is unknown. The
similar results obtained with ATR and ETV1 in the TERT
expression experiments of Figure 3 (and Figure S3) raised the
possibility that the two proteins act in a common pathway. To
address this possibility, we first asked whether ATR regulates
ETV1 levels. The immunoblot results of Figure 5A show that in
both p53+ and p532 HCT116 cells knockdown of ATR resulted
in reduced ETV1 protein levels. The qRT-PCR results of
Figure 5B showed that ATR depletion did not lead to reduced
ETV1 mRNA levels, indicating that the ATR-mediated regulation
of ETV1 occurs post-transcriptionally. Addition of an ATR
chemical inhibitor also led to reduced ETV1 protein levels in both
p53+ and p532HCT116 cells (Figure 5C). Following inhibition of
ATR activity, DNA damage did not result in ETV1 stabilization
(Figure S8).
To test the generality of these results, we analyzed the effect
of ATR pharmacological inhibition in several of the p53+ and
p532 cell lines described above. Figure 5D shows that ATR
inhibition reduced TERT protein levels in p532 RKO, NCI-
H522 and NCI-H1299 cells but not in p53+ RKO, A549 and
NCI-H460 cells Moreover, addition of an ATR inhibitor
reduced ETV1 levels to varying extents in all cell lines. TERT
protein levels were also reduced following knockdown of ATR
or ETV1 in NCI-H522 cells and two additional human cancer
cell lines that express mutant p53 (Figure S9A), as well as in
HeLa cells, which lack p53 activity due to expression of the
human papilloma virus E6 protein (Figure S9B). Thus, the
results in these other p53+ and p532 cell lines are similar to
those obtained in the isogenic pair of HCT116 cell lines used
throughout this study.
Because ATR is a protein kinase, a likely mechanism for the
ability of ATR to post-transcriptionally regulate ETV1 is
through direct interaction and phosphorylation. Consistent with
this possibility, ETV1 contains five potential ATR phosphory-
lation sites (Figure 6A). To test this idea, we ectopically
expressed a FLAG-tagged ETV1 derivative (Figure S10) in
p53+ and p532 HCT116 cells, and analyzed interaction
between FLAG-ETV1 and ATR in a co-immunoprecipitation
assay. The results of Figure 6B show that in both p53+ and
p532 HCT116 cells, FLAG-ETV1 could be detected in the
ATR immunoprecipitate (left) and, conversely, ATR could be
detected in the FLAG immunoprecipitate (right), indicating
ATR and ETV1 physically associate. To determine whether
ETV1 was an ATR substrate, we immunoprecipitated FLAG-
ETV1 from transfected p53+ and p532 HCT116 cell lysates
and analyzed the immunoprecipitate by immunoblotting with
an antibody that recognizes a phosphorylated serine followed by
a glutamine [30], the product of ATR or ATM phosphorylation
[31,32]. The results of Figure 6C show that the immunopre-
cipitated FLAG-tagged ETV1 could be detected by the ATM/
ATR phospho-specific antibody, suggestive of phosphorylation
by ATR. Moreover, following treatment of cells with an ATR
inhibitor, the immunoprecipitated FLAG-tagged ETV1 was no
longer detected by the ATM/ATR phospho-specific antibody
(Figure S11).
To confirm that ATR phosphorylates ETV1, we performed in
vitro kinase experiments. We first tested whether ATR, in the
presence of its positive effector ATRIP (NP_569055.1) [33,34],
could phosphorylate a glutathione-S-transferase (GST)-ETV1
(amino acids 1–290) fusion-protein that contained all five
potential ATR phosphorylation sites. The results of Figure 6D
show that ATR phosphorylated the GST-ETV1 fusion-protein
but, as expected, not a control GST protein. To confirm and
extend this result, we constructed and analyzed a series of GST-
ETV1 fusion-proteins each containing a single potential ATR
phosphorylation site. The results of Figure 6E show that only one
of the five potential ATR phosphorylation sites (SQ2) was a
substrate for ATR. Collectively, the results described above
indicate that ATR phosphorylates ETV1 and stabilizes it from
proteolytic degradation.
Figure 3. ETV1 and ATR are preferentially required for TERT expression in p532 cells. (A) Immunoblot analysis showing TERT levels in
p53+ and p532 HCT116 cells expressing NS, ATR or ETV1 shRNAs. The results using two unrelated ATR or ETV1 shRNAs are shown. b-actin (ACTB) was
monitoring as a loading control. (B) qRT-PCR analysis monitoring TERT expression in p53+ and p532 HCT116 cells expressing NS, ATR or ETV1
shRNAs. TERT expression was normalized to that obtained with a NS shRNA, which was set to 1. Error bars represent SD. (C) Immunoblot analysis
showing TERT levels in p53+ and p532 HCT116 cells treated with the ATR inhibitor CGK733 (left; 0, 2, 3, 4, and 5 mM) or ETP46464 (right; 0, 0.5, 1, 2, 4
and 8 mM).
doi:10.1371/journal.pgen.1003151.g003
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
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ETV1 and ATR Are Bound to the TERT Promoter in p532
but Not p53+ Cells
As discussed above, previous studies have shown that ETV1
is a transcriptional activator of TERT [26]. Therefore, we
thought the most likely mechanism by which ETV1 promotes
proliferation in p532 HCT116 cells is through direct binding
to the TERT promoter and stimulation of TERT transcription.
To test this possibility, we performed chromatin-immunopre-
cipitation (ChIP) experiments. The ChIP experiments of
Figure 7A (left panel) show that in p532 HCT116 cells,
Figure 4. RNAi–mediated knockdown of ATR, ETV1, or TERT induces senescence and prolongs G2/M preferentially in p532 cells. (A)
Senescence-associated b-galactosidase assay in p53+ and p532 HCT116 cells expressing a NS shRNA or one of two unrelated TERT shRNAs.
Senescence-associated b-galactosidase activity was normalized to that obtained using a NS shRNA, which was set to 1. Error bars represent SD. (B)
Senescence-associated b-galactosidase assay in p53+ and p532 HCT116 cells expressing a NS, ATR or ETV1 shRNA. Senescence-associated b-
galactosidase activity was normalized to the level obtained using a NS shRNA, which was set to 1. Error bars represent SD. (C) Table showing the
percentage of cells in G1, S and G2/M in p53+ and p532 HCT116 cells expressing a NS shRNA or one of two unrelated TERT shRNAs. (D) Table
showing the percentage of cells in G1, S and G2/M in p53+ and p532 HCT116 cells expressing a NS shRNA or one of two unrelated ATR or ETV1
shRNAs. (E) Proliferation of p53+ and p532 HCT116 cells transfected with a control (LMNA), ATR or ETV1 siRNA and stably expressing TERT, or as a
control GFP, was determined by an Alamar Blue fluorescence assay. Cell proliferation was normalized to that obtained using a LMNA siRNA, which
was set to 1. Error bars represent SD.
doi:10.1371/journal.pgen.1003151.g004
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
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ETV1 was bound to a region within intron 1, which has been
previously reported to contain multiple ETV1 binding sites
and is required for complete TERT transcriptional activity
[26]. Remarkably, in p53+ HCT116 cells, whose proliferation
is not dependent upon ETV1, there was no detectable binding
of ETV1 to the same region of the TERT promoter. Notably,
ectopic expression of wild type p53 in p532 HCT116 cells
resulted in substantially decreased binding of ETV1 to the
TERT promoter (Figure 7B, left). Conversely, ectopic expres-
sion of a p53 dominant-negative mutant in p53+ HCT116 cells
resulted in substantially increased binding of ETV1 to the
TERT promoter (Figure 7B, right).
In p532 HCT116 cells, binding of ETV1 to the TERT
promoter was lost following pharmacological inhibition of ATR
(Figure 7A and Figure S12A), which as shown above results in
decreased ETV1 levels (see Figure 5C). Conversely, binding of
ETV1 to the TERT promoter modestly increased following
irradiation with ultraviolet light, which increases ATR activity
(Figure S12B). ChIP experiments monitoring ATR occupancy
revealed that ATR was bound to the same region of the TERT
promoter as ETV1 (Figure 7C). Thus, in p532 HCT116 cells,
ETV1 and ATR are both bound to the TERT promoter, which is
consistent with our finding that the two proteins are physically
associated (Figure 6B).
In conjunction with a previous study [26], the results
presented above suggested that ETV1 is directly responsible
for stimulating TERT expression and that ATR functions by
phosphorylating and thereby stabilizing ETV1. A prediction of
this model is that ectopic expression of ETV1 would bypass the
requirement of ATR for proliferation of p532 HCT116 cells.
The rescue experiment of Figure 7D shows that the decreased
proliferation of p532 HCT116 cells following knockdown of
ATR was counteracted by ectopic expression of ETV1 (Figure
S13). Following knockdown of TERT, ectopic expression of
ETV1 could no longer rescue proliferation of p532 HCT116
cells depleted of ATR (Figure S14A). In these experiments,
ectopic expression of ETV1 had no effect on c-H2AX foci
formation, a marker of DNA damage [35] (Figure S14B).
These results suggest that the growth arrest observed following
loss of ATR is primarily due to decreased ETV1 levels.
Figure 5. ATR is required for ETV1 stabilization. (A) Immunoblot analysis showing ETV1 levels in p53+ and p532 HCT116 cells expressing a NS,
ATR or ETV1 shRNA. a-tubulin (TUBA) was monitoring as a loading control. (B) qRT-PCR analysis monitoring ETV1 expression in p53+ and p532
HCT116 cells expressing a NS, ATR or ETV1 shRNA. ETV1 expression was normalized to that obtained with a NS shRNA, which was set to 1. Error bars
represent SD. (C) Immunoblot analysis showing ETV1 levels in p53+ and p532 HCT116 cells treated with CGK733 (left; 0, 2, 3, 4 and 5 mM) or
ETP46464 (right; 0, 0.5, 1, 2, 4 and 8 mM). (D) Immunoblot analysis showing TERT and ETV1 levels in p53+ and p532 RKO cells, as well as A549, NCI-
H460, NCI-H522 and NCI-H1299 cells treated with CGK733 (top; 0, 2 and 4 mM) or ETP46464 (bottom; 0, 0.5, 1, 2, 4 and 8 mM).
doi:10.1371/journal.pgen.1003151.g005
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Discussion
In this report we have performed a large-scale shRNA screen
to identify a regulatory pathway involving ETV1, ATR and
TERT that is preferentially required for proliferation of diverse
p532 cancer cells. We found that in p532 cells, TERT
transcription is highly dependent upon ETV1, which functions
as a direct transcriptional activator by binding to the TERT
promoter downstream of the transcription start-site. In p53+ cells,
ETV1, although present at comparable levels, is not required for
TERT transcription and surprisingly is not bound to the same
region of the TERT promoter. Notably, ectopic TERT expression
restored normal proliferation in p532 cells depleted of ETV1 or
ATR (Figure 4E and Figure S7A), indicating that the promotion
of TERT expression is an important, but not necessarily the only,
mechanism by which ETV1 and ATR maintain proliferation of
p532 cells. Consistent with our results, a previous study reporting
a requirement for ETV1 in TERT transcription [26] was
primarily based upon experiments performed in 293T cells,
which lack p53 activity due to expression of SV40 large T
antigen.
The results described above suggest that p53+ cells express a
transcription factor that functionally substitutes for ETV1, and
that one or more proteins associated with the TERT promoter in
p53+ cells prevent binding of ETV1. Several transcription factors,
including SP1 (NP_612482.2), E2F1 (NP_005216.1) and MYC
(NP_002458.2), have been previously shown to be associated with
the human TERT promoter (reviewed in [36]). To ask whether
these factors, or p53 itself, might contribute to the differential
regulation of TERT we performed ChIP experiments in p53+ and
p532 HCT116 cells. Consistent with previous studies, we found
that E2F1 and MYC were associated with the TERT promoter;
binding of E2F1 was modestly increased in p532 HCT116 cells
(Figure S15A), whereas for MYC there was no difference in p53+
and p532 HCT116 cells (Figure S15B). In p53+ HCT116 cells
there was increased binding of SP1 (Figure S15C) and, most
notably, there was substantial binding of p53 to the TERT
promoter (Figure S15D). Interestingly, a number of previous
studies have reported physical and functional interactions between
SP1 and p53 (see, for example, [37–41]). Our ChIP results reveal
substantial differences between the composition of proteins
associated with the TERT promoter in p53+ and p532
HCT116 cells, which may be related to the differential require-
ment for ETV1.
Interestingly, in contrast to human cancer cell lines, we found
that ATR was not required for TERT expression in experimentally
derived p532 MCF10A cells, an immortalized but non-trans-
formed human cell line (Figure S16A). In addition, ATR was not
required for TERT expression in p532 mouse embryo fibroblasts
(Figure S16B), consistent with the lack of conservation between the
mouse and human TERT promoter (data not shown). Thus, the
Figure 6. ATR interacts with and phosphorylates ETV1. (A) (Left) Schematic of the full-length ETV protein, showing the positions of the five
potential ATR phosphorylation sites (SQ). (Right) Sequence surrounding each potential phosphorylation site, and the consensus ATR phosphorylation
site. (B) Co-immunoprecipitation assay. Cell extract from p53+ or p532 HCT116 cells expressing FLAG-ETV1 was immunoprecipitated using an ATR
antibody and the immunoprecipitate analyzed by immunoblotting for FLAG (left), or immunoprecipitated using a FLAG antibody and the
immunoprecipitate analyzed by immunoblotting for ATR (right). IgG was used as a specificity control. (C) Extract from p53+ or p532 HCT116 cells
expressing FLAG-ETV1 was immunoprecipitated using a FLAG antibody and the immunoprecipitate analyzed by immunoblotting using an antibody
that recognizes ETV1 or a phosphorylated SQ motif (P-SQ). (D) In vitro kinase assay monitoring the ability of ATR to phosphorylate a GST-ETV1 (amino
acids 1–290) fusion protein containing all five potential SQ phosphorylation sites or, as a control, GST alone. Autoradiographic images (Autorad, top)
and corresponding silver-stained gels (SS, bottom) are shown. (E) In vitro kinase assay monitoring the ability of ATR to phosphorylate a series of GST-
ETV1 fusion proteins, each containing 15 amino acids encompassing a potential SQ phosphorylation site (sequences shown in A) or, as a control, GST
alone. Autoradiographic images (Autorad, top) and corresponding silver-stained gels (SS, bottom) are shown. The position of the 32P-labeled fusion
protein is indicated by the arrow.
doi:10.1371/journal.pgen.1003151.g006
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requirement of ATR and ETV1 for TERT expression may be
specific to human p532 cancer cell lines.
Several previous studies have reported results that are consistent
with the synthetic interaction between p53 and ATR we have
described here. For example, p532 cells have been found to be
particularly sensitive to pharmacological inhibition of ATR (see,
for example, [42–44]). In addition, mice expressing a hypomor-
phic allele of ATR have an aging phenotype that is exacerbated in
the absence of p53 [45]. Significantly, mouse embryo fibroblasts
containing this hypomorphic ATR allele have an elongated G2
phase following loss of p53, consistent with our cell cycle results
(Figure 4D and Figure S6B, S6C). However, a preferential role for
ETV1 in p532 cells and its cooperative function with ATR has
not been previously described and underscores the power of
unbiased, large-scale RNAi-based screens.
Our screening strategy did not emphasize reaching saturation
but rather sought to follow-up, by directed experiments, a limited
number of candidates isolated in the primary screen. For several
reasons, we believe that our screen, like other large-scale shRNA
screens (see, for example, [46]), did not achieve saturation. For
example, a previous siRNA screen identified several factors, in
particular the serine/threonine kinase receptor-associated protein
UNRIP (also called STRAP; NP_009109.3), whose loss affected
proliferation of p532 HCT116 cells more severely than p53+
HCT116 cells [47]. However, we did not isolate UNRIP in our
primary screen and, conversely, ATR and ETV1 were not isolated
in the previous siRNA screen, suggesting that neither screen was
truly saturating. Reasons for a failure to reach saturation in this
and other large-scale shRNA screens include suboptimal efficacy
of some shRNAs [48], unequal representation of shRNAs in the
primary screen, and an insufficient depth of deep sequencing.
Thus, it is possible that additional factors that act in the ATR-
ETV1-TERT pathway, or unrelated pathways preferentially
required for proliferation of p532 cells, remain to be identified.
The decreased proliferation of p532 cell lines was first evident
within a few days following knockdown of ETV1, ATR or TERT.
It therefore seems likely that this reduced proliferation is not a
result of replicative senescence due to telomere attrition, which
would require many cell divisions. Senescence occurred at much
later times (10–14 days) and may be a secondary effect of the
proliferation block. We observed that knockdown of ETV1, ATR
or TERT resulted in an increased percentage of cells in G2/M
(Figure 4C, 4D and Figure S6). Although senescent cells are
generally believed to arrest in G1, it has been found that senescent
cells can also arrest in G2/M (see, for example, [49]).
A variety of previous studies have shown that TERT can
promote proliferation by multiple mechanisms, several of which
are unrelated to telomere length including inhibiting apoptosis
[50], regulating cell signaling pathways and/or stimulating
expression of diverse growth-promoting genes (see, for example,
[51–54]). It seems likely that the decreased proliferation of p532
cells following depletion of ETV1, ATR or TERT involves one of
Figure 7. ATR and ETV1 are bound to the TERT promoter in p532 but not p53+ cells. (A) ChIP analysis monitoring ETV1 occupancy at two
regions of the TERT promoter, in the first intron or 3 kb upstream of the transcription start-site, in p53+ and p532 HCT116 cells treated in the
presence or absence of CGK733. The locations of the primer pairs (arrows) and ETV1-binding sites (red rectangles) are shown in the schematic of the
TERT promoter (bottom). Error bars represent SD. (B) ChIP analysis monitoring ETV1 occupancy at two regions of the TERT promoter in p532 HCT116
cells expressing wild type p53 (p53-WT) or a vector control (left) and in p53+ HCT116 cells expressing a dominant negative p53 mutant (p53-DD) or a
vector control (right). Error bars represent SD. (C) ChIP analysis monitoring ATR occupancy at two regions of the TERT promoter in p53+ and p532
HCT116 cells treated in the presence or absence of CGK733. Error bars represent SD. (D) Proliferation of p53+ and p532 HCT116 cells stably
expressing ETV1 or, as a control, empty vector was determined by an Alamar Blue fluorescence assay. Proliferation was normalized to that obtained
using a LMNA siRNA, which was set to 1 (not shown). Error bars represent SD.
doi:10.1371/journal.pgen.1003151.g007
ATR-ETV1-TERT Pathway for p532 Cell Proliferation
PLOS Genetics | www.plosgenetics.org 9 December 2012 | Volume 8 | Issue 12 | e1003151
these alternative mechanisms. We have found that p532 cells
depleted of ETV1, ATR or TERT have multiple growth defects
including increased levels of senescence (Figure 4A, 4B and Figure
S5) and an altered cell cycle (Figure 4C, 4D and Figure S6). A
further understanding of how TERT promotes proliferation of
p532 cells is likely to identify new factors that are potential
therapeutic targets.
Materials and Methods
Ethics Statement
Animal experiments were performed in accordance with the
Institutional Animal Care and Use Committee (IACUC) guide-
lines.
Cell Lines and Culture
Isogenic p53+ and p532 HCT116 and RKO cell lines [20]
were provided by B. Vogelstein; A549, NCI-H460, NCI-H522,
NCI-H1299 and HT29 cells were obtained from the National
Cancer Institute; and DLD-1, HeLa and MCF10A cells were
obtained from the American Type Culture Collection. The basis
for the p532 status in each of the p532 cell lines is provided in
Table S3. p53+ and p532 mouse embryonic fibroblasts were
isolated from wild type and p532/2 C57BL/6 mice. All cells were
grown according to the supplier’s recommendations. Stable A549
and MCF10A cell lines expressing p53-DD, which harbors a
deletion of 288 amino acids (D15-301; [23]) were generated by
transfection with the plasmid pBABE-hygro-p53DD (Addgene;
[55]) or the control vector, pBABE-hygro, and selection with
hygromycin (150–200 mg/ml). Stable p53+ and p532 HCT116
cell lines expressing TERT were generated by transfection with
the plasmid pWZL-Blast-Flag-HA-hTERT (Addgene; [56]) or
control plasmid pWZL-Blast-GFP (Addgene; [57]), and selection
with blasticidin (10 mg/ml). The ETV1 expression vector was
generated by subcloning ETV1 cDNA (Open Biosystems) into
pEF6-Blast-3xFlag to create pEF6-Blast-3xFlag-ETV1. The pEF6-
Blast-3xFlag vector was generated by cloning a BsiWI-EcoRI
double-stranded oligo coding for 3xFlag-tag (MDYKDHDG-
DYKDHDIDYKDDDDKEF) in Kpn1-EcoR1-digested pEF6/
V5-HIS B (Invitrogen). Stable p53+ and p532 HCT116 cell lines
expressing ETV1 were generated by transfection with pEF6-Blast-
3xFlag-ETV1 or vector only and selection with blasticidin (10 mg/
ml).
RNAi Screening
The Open Biosystems GIPZ lentiviral human shRNAmir
library was obtained through the University of Massachusetts
Medical School RNAi Core Facility. Twelve lentiviral pools, each
comprising ,5000 shRNA clones, were generated with titers of
,26106 pfu/ml. These lentiviral stocks were produced following
co-transfection with the packaging mix into the 293T packaging
cell line. To carry out the screen, p53+ and p532 HCT116 cells
were plated at 16106 cells per 100 mm plate, transduced the next
day with one shRNA pool per plate at a multiplicity of infection
(MOI) of 1, and grown in the absence of puromycin selection.
Forty hours after transduction, 75% of cells were transduced (as
evidenced by GFP fluorescence; the marker turboGFP is present
in the pGIPZ vector). Each plate was divided into two populations:
half of the cells were pooled and genomic DNA was extracted
(referred to as ‘‘T0’’), whereas the other half were transferred to
150 mm plates and passaged by 4-fold dilutions for 10 days, at
which point the cells were pooled and the genomic DNA was
extracted (referred to as ‘‘T10’’).
Deep Sequencing
To analyze the frequency of individual shRNAs in the four
populations, 72 mg of genomic DNA was used as the substrate
(split into 24 tubes) and PCR amplified (94uC for 1 min; 15 cycles
of 94uC for 1 min, 58uC for 1 min, 72uC for 45 sec; 72uC for
10 min; and hold at 4uC) with primers GIPZF (59-
GAGTTTGTTTGAATGAGGCTTCAGTAC-39) and GIPZHR
(59-CGCGTCCTAG GTAATACGAC-39). The PCR product
was gel purified, and 50 ng of DNA was used as the substrate for a
second PCR amplification (94uC for 1 min; 15 cycles of 94uC for
1 min, 50uC for 1 min, 72uC for 45 sec; 72uC for 10 min; and
hold at 4uC) using primers Forward Acu1 primer AMN (59-
CAACAGAAGGCTCCTGAAGGTATATTGCTGTTGAC-39)
and Reverse Acu1 primer AMN (59-AAATTTAAACTGAAG-
TACATCTGTGGCTTCACTA-39). Next, 1 mg of the PCR
product was digested to completion with AcuI (New England
Biolabs). The digested product was then ligated to the following
pre-annealed adapters: L1ShSolexA (/5Bio/-ACACTC
TTTCCCTACACGACGCTCTTCCGATCTCA) and L1ShSo-
lexB (/5Phos/9-AGATCGGAAGA GCGTCGTGTAGGGAAA-
GAGTGT/3AmM, and L2ShSolexB (/5Phos/-AGATCGGAA-
GAGC TCGTATGCCGTCTTCTGCTTG/3Bio/) and
L2ShSolexA (/5AmMC6/-CAAGCAGAAGACG GCATAC-
GAGCTCTTCCGATCTAC). The product of the 3-way ligation
was run on a 3% TAE agarose gel, visualized with ethidium
bromide, purified and used as a substrate for a 15-cycle PCR
reaction using Solexa-Illumina primers 1.1 and 2.1 and the cycling
conditions recommended by the manufacturer.
The library was analyzed using the Solexa-Illumina GA
Massively Parallel Deep Sequencer. Sequence information was
extracted from the image files using the Solexa-Illumina Firecrest
and Bustard applications. Prior to alignment of the sequence
reads, a custom Perl script was used to identify the first six bases
flanking the informative sequence in 59 and the six bases flanking
the informative sequence in 39, starting at position 28. The core
21 bp sequences were extracted and mapped to the human
reference genome sequence (hg18) using the Solexa-Illumina
ELAND algorithm, allowing up to two mismatches to the
reference sequence. No further analysis was performed on reads
that did not contain the six bases of the 59 sequence or the six
bases of 39 adapter sequence.
Sequences mapping to the same genomic location were binned
and the count for each of the mapped genomic sequences was
calculated for each of the four treatments. For each of the mapped
genomic sequences, the Fisher Exact Test was applied to assess
whether there was a differential depletion/enrichment of the
shRNA sequences between T0 and T10 for both the p532 and
p53+ HCT116 cell lines. The odds ratio and its 95% confidence
interval were computed for each of the mapped genomic
sequences using Fisher test function in R v2.8 based on conditional
maximum likelihood estimation. To adjust for multiplicity, B–H
method [58] was used. Those shRNAs with an adjusted p-
value,0.01 and a decrease of at least four-fold at T10 compared
with T0 in p532 HCT116 cells and no more than two-fold in
p53+ HCT116 (or adjusted p-value$0.01) were identified. The
data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus [59] and are accessible through GEO
Series accession number GSE15967 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc =GSE15967).
Colony Formation Assay
Lentiviral supernatants corresponding to individual shRNAs
(listed in Table S4) were generated in 293T cells as described
above. p53+ and p532 HCT116 cells were transduced with each
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lentiviral preparation at an MOI of 0.2–0.4, and grown for 10
days without puromycin selection, during which cells were
passaged at a 1:6 ratio every 4 days. Cells were then subjected
to puromycin selection (1.5 mg/ml) for 5 days. For colony
formation assays, cells were split at a 1:200 ratio and plated in
6-well plates in the presence of 1.5 mg/ml puromycin. After 6–7
days, cells were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS) at 4uC overnight and then stained with 0.1%
crystal violet in PBS to visualize the colonies. At least two
independent infections were performed for each shRNA; repre-
sentative images are shown.
Alamar Blue Assays
For shRNA-based experiments, cells were transduced with
lentiviral supernatants at an MOI of 0.2–0.4, and subjected to
puromycin selection (1.5 mg/ml) for 5 days. Cells were then
passaged at a 1:8 ratio every 3 days and cultured in growth
medium containing puromycin. After 4 passages, cells were split at
a 1:6 ratio and seeded in a 12-well plate in RPMI medium without
phenol red and supplemented with 5% fetal calf serum. After 18 h,
the medium was replaced with 500 ml of medium containing 10%
of an Alamar Blue solution (Invitrogen). After 2 h, 100 ml of the
medium was used to measure fluorescence by excitation at 530 nm
and emission at 590 nm. For siRNA-based experiments, siRNA
duplexes were transfected into cells using Lipofectamine RNAi-
Max Transfection Reagent (Invitrogen) according to the manu-
facturer’s instructions. Briefly, 1.2 ml of Lipofectamine was
complexed with the siRNA (40 nM final concentration), and the
solution was diluted with 100 ml of medium and applied to 26104
cells in a volume of 500 ml culture medium per well in 24-well
plates. The medium was changed after 24 h and proliferation
assessed by Alamar Blue fluorescence after an additional 72 h.
Sequences of siRNAs are listed in Table S4; the control LMNA
siRNA sequence was previously described [60]. All experiments
were performed at least 2–3 times in either duplicate or triplicate.
Trypan Blue Cell Counting
Four days post-siRNA-transfection, cells were trypsinized,
resuspended in 0.5 ml growth medium, and stained with 0.5 ml
0.1% Trypan blue solution (HyClone Trypan blue, Thermo Fisher
Scientific). Viable cells were counted using a Countess Automated
Cell Counter (Life Technologies). Two independent transfections
were carried out and analyzed in duplicate.
Tumor Formation Assays
26106 shRNA-transduced p53+ or p532 HCT116 cells were
suspended in 100 ml of serum-free RPMI and injected subcuta-
neously into the opposite flanks of n= 9 (for non-silencing and
ATR shRNAs) or n = 5 (for ETV1 shRNA) athymic Balb/c (nu/
nu) mice (Taconic). Tumor dimensions were measured every week
and tumor volume was calculated using the formula p/
66(length)6(width)2. A Mann-Whitney test was used to determine
whether knockdown of ATR or ETV1 changes the tumor volume
at week 4 compared to a non-silencing shRNA.
Antibodies and Immunoblot Analysis
Cell extracts were prepared by lysis in modified RIPA buffer
(0.05 M Tris-Cl [pH 8.0], 0.15 M NaCl, 1% Nonidet P-40, 0.5%
desoxycholate, 0.1% SDS, 2 mM phenylmethylsulphonyl fluoride
(PMSF), 20 mg/ml aprotinin, 1 mM Na3VO4 and 1 mM NaF) in
the presence of a proteinase inhibitor cocktail (Roche). Blots were
probed with a-TERT (Epitomics, 1531-1). a-ETV1 (Abcam,
ab81086), a-Flag M2 (Sigma, F1804), a-phospho-CHK1(Ser317)
(Cell Signaling Technology, 8191), a-p21 (BD Pharmingen,
SX118), a-tubulin (Sigma, B5-1-2) or b-actin (Sigma, AC74).
For ATR inhibition, cells were treated with 2–6 mM CGK733
(Calbichem) or 0.5–8 mM ETP46464 ([29]; kindly provided by O.
Fernandez Capetillo) for 72 h prior to cell extract preparation; as a
control, cells were treated with dimethyl sulfoxide (DMSO). For
p53 functional assays (Figure S1), cells were treated with 25 mM
etoposide (Sigma) or 10 mg/ml 5-fluorouracil (Sigma) for 24 h,
and cell extracts were prepared as above. For RNAi experiments,
experiments were performed at least 2–3 times in either duplicate
or triplicate.
qRT–PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen)
and treated with Turbo DNA-free kit (Ambion Inc.). The same
amount of total RNA (3 mg) for each sample was employed to
produce templates for SYBR-green quantitative PCR analysis
using SuperScript II Reverse transcriptase (Invitrogen). Target
genes were amplified using specific primers and expression levels
were normalized to that of GAPDH. Primer sequences are listed in
Table S4. All experiments were performed at least 2–3 times in
either duplicate or triplicate.
Senescence-Associated b-Galactosidase Assays
Assays were performed as described previously [61] with minor
modifications. Briefly, 10–14 days following RNAi-mediated
knockdown, cells were washed twice with PBS, then fixed using
3.7% paraformaldehyde for 5 min at room temperature. After
three washes with PBS, cells were incubated with fresh staining
solution (40 mM citric acid/Na2HPO4 pH 6.0, 150 mM NaCl,
2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide, 1 mg/ml X-Gal) for 12–18 hr at 37uC (no CO2) and
covered from light. Images were captured using a Spot TE-200
digital camera (SPOT Imaging Solutions). The number of blue
cells in 10 fields (each containing 100–250 cells) was counted
manually, and the percentage calculated. Two independent
infections were performed for each knockdown.
Cell Cycle Analysis
Cells transduced with shRNAs were harvested by trypsinization,
fixed in 80% ethanol and stored at 220uC overnight. Fixed cells
were stained with propidium iodide buffer containing 50 mg/ml
RNase (Sigma) and 50 mg/ml propidium iodide (Sigma) in PBS.
Flow cytometry was performed by the UMass Medical School
Core Flow Cytometry Lab using a FACScalibur flow cytometer
(Becton Dickinson). Data were analyzed with FlowJo (Tree Star).
All experiments were performed at least 2–3 times.
Co-Immunoprecipitation Assays
For Figure 6B, 56107 p53+ or p532 HCT116 cells expressing
Flag-ETV1 were rinsed twice with cold PBS, lysed in 1 ml IP lysis
buffer (50 mM Tris-Cl pH 7.4, 250 mM NaCl, 5 mM EDTA,
0.2%Triton X-100, 0.5 mM DTT, 16 complete protease
inhibitor [Roche], and phosphatase inhibitor cocktails 2 and 3
[Sigma, p5726 and p0044]) on ice. The lysate was cleared by
centrifugation at 16,000 g for 30 min at 4uC. Whole cell lysate
(2 mg per sample) was incubated with relevant antibodies (a-ATR
[Abcam, ab2905] or control rabbit IgG [Abcam, ab37415] or a-
Flag M2 [Sigma] or control mouse IgG [Santa Cruz, sc2343])
overnight at 4uC after being precleared with 50 ml Dynabeads-
protein G (Invitrogen). Dynabeads Protein G (50 ml) were added to
each lysate-antibody complex, incubated for 2 h, spun, and
washed 5 times with IP lysis buffer. Protein complexes were
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eluted by boiling with Laemmli buffer. For Figure 6C, immuno-
precipitations were carried out as described above with a-Flag M2
(Sigma), then immunoblotted with a-SQ2 ([30]; kindly provided
by S. Elledge), or a-ETV1 (Abcam).
In Vitro Kinase Assays
To create GST-ETV1 (amino acids 1–290), the corresponding
portion of ETV1 was PCR amplified using pEF6-Blast-3xFlag-
ETV1 as a template and cloned into pGEX-4T-3 (GE
Healthcare). The construct was confirmed by sequencing. For
the smaller GST-ETV1 fusion proteins, synthetic oligos corre-
sponding to amino acids 9–23 (SQ1), 44–58 (SQ2), 97–111 (SQ3),
165–179 (SQ4) or 240–254 (SQ5) were annealed and cloned into
pGEX-4T-3. In vitro kinase assays were performed as previously
described [62] except that reaction volumes were quadrupled. 32P-
labeled products were visualized by autoradiography.
Chromatin Immunoprecipitation Assays
ChIP assays were carried out as described previously [63,64]
with the following minor modifications. Briefly, 56107 cells were
first incubated with ethylene glycol bis(succinimidyl succinate)
(EGS) for 30 min and then incubated with 1% formaldehyde for
10 min at room temperature before crosslinking was quenched by
addition of 0.125 M glycine. Cells were collected by centrifugation
and lysed in lysis buffer containing 50 mM Tris–HCl pH 8.0,
10 mM EDTA, 0.5% SDS, proteinase inhibitors (Roche) and
phosphatase inhibitors (Sigma). The cell suspension was sonicated
for 15 min total time with 30 seconds ON and 30 seconds OFF
using Bioruptor (Diagenode). Sonicated chromatin was then
incubated at 4uC overnight with 5 mg of the appropriate antibody:
a-ATR (Abcam), a-ETV1 (Abcam), a-E2F1 (Santa Cruz), a-MYC
(Cell Signaling Technology), a-p53 (Santa Cruz), a-SP1 (Abcam),
and corresponding IgG control. Immunoprecipitated chromatin
DNA was analyzed by real-time PCR using the following primers:
TERT promoter (23 kb) (for 59-ACGATGGAGGCAGT-
CAGTCT-39; rev 59-T CCCCACACACTTCATGCTA-39),
TERT promoter (2300 bp) (for 59-GTTCCCAGGGCCTCCA
CATC-39; rev 59-GCGGAGAGAGGTCGAATCGG-39), TERT
intron 1 (0.4 kb) (for 59-GAACC AGCGACATGCGGAGAGCA-
39; rev: 59-AGCTCCTTCAGGCAGGACACCT-39). Fold en-
richment was calculated by comparing the amplification threshold
(Ct) value of a given ChIP sample with that obtained in the IgG
control at the same target locus. All experiments were performed
at least 2–3 times in either duplicate or triplicate.
Immunofluorescence
Quantification of c-H2AX-positive cells was performed as
previously described [65] with modifications. Briefly, cells were
seeded onto 22-mm glass coverslips and 48 h later, the coverslips
were washed in PBS, incubated in cytoskeleton buffer (10 mM
piperazine-N,N9-bis[2-ethanesulfonic acid] [PIPES] pH 6.8,
100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA,
0.5% Triton X-100] for 5 min on ice. After several washes with
ice-cold PBS, the cells were fixed in 4% paraformaldehyde for
20 min and permeabilized in 0.5% Triton X-100 solution for
15 min at room temperature. Cells were blocked with 2% BSA in
PBS, incubated with primary antibody anti-phosphoH2AX
(Ser139) (Millipore, JBW301) overnight at 4uC, washed three
times with 16PBS, and incubated with secondary antibody Cy3-
conjugated sheep anti-mouse IgG (Sigma-Aldrich) for 1 h at room
temperature. Cells were then washed, counterstained with 49,69-
diamidino-2-phenylindole (DAPI), and mounted in 90% glycerol
and 2% 1,4-diaza-bicyclo-(2,2,2)-octane (DABCO). Images were
captured using a Zeiss AxioCam HRc camera, and 10 fields of
cells were counted for each sample in duplicate.
Supporting Information
Figure S1 Characterization of p53 function in the human
cancer cell lines used in this study. Immunoblot analysis
monitoring p21 levels in cell lines treated with 5-fluorouracil (5-
FU) or etoposide. The results show that in all p53+ cells, p21 levels
increased following treatment with either DNA damaging agent,
indicative of functional p53. By contrast, in all p532 cells p21
levels were reduced or undetectable following treatment with
either DNA damaging agent, confirming the absence of functional
p53.
(TIF)
Figure S2 Analysis of target gene expression following shRNA-
or siRNA-mediated knockdown in p532 HCT116 cells. (A) p532
HCT116 cells were infected with a lentivirus expressing each
individual candidate shRNA, or as a control a non-silencing (NS)
shRNA, and target gene expression was analyzed by quantitative
RT-PCR (qRT-PCR). Target gene expression was normalized to
that obtained with the NS shRNA, which was set to 1. Error bars
represent SD. (B) qRT-PCR analysis of target gene expression in
p532 HCT116 cells transfected with an siRNA directed against
an individual candidate gene or a control lamin A/C (LMNA)
siRNA. Target gene expression was normalized to that obtained
with the LMNA siRNA, which was set to 1. Error bars represent
SD.
(TIF)
Figure S3 Comparison of single versus multiple siRNA
knockdowns on proliferation and TERT expression in p532 cell
lines. (A) (Left) Proliferation of p532 HCT116 cells transfected
with single or multiple siRNAs as indicated was determined by an
Alamar Blue fluorescence assay. The results were normalized to
that obtained with the lamin A/C (LMNA) siRNA, which was set
to 1. Error bars represent SD. (Right) Immunoblot analysis
monitoring TERT levels in p532 HCT116 cells transfected with
single or multiple siRNAs as indicated. a-tubulin (TUBA) was
monitored as a loading control. (B) Proliferation of p532 A549
cells as described in panel A (left). (C) Proliferation of p532 RKO
cells as described in panel A (left). The results show that the effects
of double knockdowns were very similar to those observed
following single knockdowns.
(TIF)
Figure S4 Confirmation of inhibition of ATR by CGK733 and
ETP46464. Immunoblot analysis monitoring phospho-CHK1
(Ser317) levels in UV-irradiated (50 J/m2) p53+ and p532
HCT116 cells treated with CGK733 (top; 0, 2, 3, 4, 5 and
6 mM) or ETP46464 (bottom; 0, 0.5, 1, 2, 4 and 8 mM). a-tubulin
(TUBA) and b-actin (ACTB) were monitored as loading controls.
The results show that the levels of phospho-CHK1 (Ser317), a
target of ATR, were reduced following addition of either CGK733
or ETP46464, indicating ATR activity was inhibited.
(TIF)
Figure S5 Effect of knockdown of ETV1, ATR or TERT on
senescence induction. (A) Representative images of p53+ and
p532 HCT116 cells expressing a non-silencing (NS) shRNA or
one of two unrelated TERT shRNAs and stained for senescence-
associated b-galactosidase. (B) Representative images of p53+ and
p532 HCT116 cells expressing a NS, ATR or ETV1 shRNA
and stained for senescence-associated b-galactosidase. (C) Senes-
cence-associated b-galactosidase assay in p53+ and p532
HCT116 cells expressing a NS, ATR, ETV1 or TERT shRNA.
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Senescence-associated b-galactosidase activity was normalized to
that obtained using a NS shRNA, which was set to 1. In this
experiment, which is a replicate of that shown in Figure 4A, 4B,
the effects of ATR, ETV1 and TERT knockdown were analyzed
simultaneously.
(TIF)
Figure S6 FACS analysis of p53+ and p532 HCT116 cells
following knockdown of TERT, ATR or ETV1. (A) FACS
analysis of p53+ and p532 HCT116 cells expressing a non-
silencing (NS) shRNA or one of two unrelated TERT shRNAs.
(B) FACS analysis of p53+ and p532 HCT116 cells expressing
a NS shRNA or one of two unrelated ATR or ETV1 shRNAs.
(C) FACS analysis of p53+ and p532 HCT116 cells expressing
a NS, TERT, ATR or ETV1 shRNA. In this experiment,
which is a replicate of that shown in panels A and B, the effects
of ATR, ETV1 and TERT knockdown were analyzed
simultaneously. The percentage of cells in G1, S and G2/M
is indicated.
(TIF)
Figure S7 Restoration of proliferation following ectopic ex-
pression of TERT following ETV1 or ATR knockdown. (A)
Proliferation of p53+ and p532 HCT116 cells transfected with a
control (lamin A/C; LMNA), ATR or ETV1 siRNA and stably
expressing TERT, or as a control GFP, was determined by
counting cells. Cell number was normalized to that obtained
using a LMNA siRNA in p53+/GFP cells, which was set to 1.
Error bars represent SD. (B) Immunoblot analysis monitoring
TERT levels in p53+ and p532 HCT116 cells stably transfected
with a plasmid expressing TERT or, as a control, green
fluorescent protein (GFP). The upper and lower bands represent
ectopic FLAG-HA-TERT and endogenous TERT, respectively,
as indicated. a-tubulin (TUBA) was monitored as a loading
control.
(TIF)
Figure S8 In the absence of ATR kinase activity DNA damage
does not stabilize ETV1. Immunoblot analysis monitoring ETV1
levels in p532 HCT116 cells in the presence or absence of
irradiation with ultraviolet (UV) light or treatment with ETP46464
as indicated. a-tubulin (TUBA) was monitoring as a loading
control.
(TIF)
Figure S9 ATR and ETV1 promote TERT expression in
human cancer cell lines expressing a p53 mutant and in HeLa
cells. (A) Immunoblot analysis monitoring TERT levels in various
human cancer cell lines expressing a p53 mutant transfected with a
non-silencing (NS), ATR or ETV1 shRNA. a-tubulin (TUBA) was
monitoring as a loading control. (B) Immunoblot analysis
monitoring TERT levels in HeLa cells transfected with a control
(lamin A/C; LMNA), ATR or ETV1 siRNA. b-actin (ACTB) was
monitored as a loading control. The results show that ATR and
ETV1 are required for TERT expression human cancer cell lines
expressing a p53 mutant (panel A) or in which wild type p53 is
inactivated by expression of human papilloma virus E6 protein
(panel B).
(TIF)
Figure S10 Confirmation of increased ETV1 levels upon ectopic
expression. Immunoblot analysis monitoring FLAG-ETV1 levels
in p53+ and p532 HCT116 cells stably transfected with a plasmid
expressing FLAG-ETV1 or, as a control, empty vector. The upper
band represents FLAG-ETV1, and the lower signal is a non-
specific band.
(TIF)
Figure S11 Inhibition of ATR kinase activity results in loss of
ETV1 SQ phosphorylation. p53+ HCT116 cells expressing
FLAG-ETV1 were treated in the presence or absence of
CGK733. Subsequently, extracts were prepared and immunopre-
cipitated using a FLAG antibody and the immunoprecipitate
analyzed by immunoblotting using an antibody that recognizes
ETV1 or a phosphorylated serine-glutamine motif (P-SQ).
(TIF)
Figure S12 Analysis of ETV1 occupancy on the TERT
promoter following treatment with ETP46464 or UV irradation.
(A) ChIP analysis monitoring ETV1 occupancy at two regions of
the TERT promoter, in the first intron or 3 kb upstream of the
transcription start-site, in p53+ and p532 HCT116 cells treated in
the presence or absence of ETP46464 (5 mM). Error bars
represent SD. The results confirm the ATR dependency of
ETV1 binding to the TERT promoter, shown in Figure 7A, using
a different ATR inhibitor. (B) ChIP analysis monitoring ETV1
occupancy in the TERT first intron in p532 HCT116 cells that
were or were not irradiated with UV light (50 J/m2) in the
presence or absence of ETP46464 (5 mM). The results show that
DNA damage, which activates ATR, modestly increases binding
of ETV1 to the TERT promoter.
(TIF)
Figure S13 ETV1 can be ectopically expressed at detectable
levels in ATR knockdown cells. Immunoblot analysis monitoring
FLAG-ETV1 levels in p532 HCT116 cells stably transfected with
a plasmid expressing FLAG-ETV1 or, as a control, empty vector
and also transfected with a control (lamin A/C; LMNA) or one of
two independent ATR siRNAs as indicated. b-actin (ACTB) was
monitored as a loading control.
(TIF)
Figure S14 Ectopic expression of ETV1 requires TERT to
restore proliferation in p532 HCT116 cells following ATR
knockdown and does not induce DNA damage. (A) Proliferation of
p532 HCT116 cells stably expressing ETV1, or the empty
expression vector, were transfected with single or multiple siRNAs
as indicated. Proliferation was determined by an Alamar Blue
fluorescence assay. The results were normalized to that obtained
with the control (lamin A/C; LMNA) siRNA, which was set to 1.
Error bars represent SD. (B) p532 HCT116 cells stably expressing
ETV1, or the empty expression vector, were transfected with a
non-silencing (NS) or ATR shRNA. Cells were stained for c-
H2AX, a marker of double-strand breaks (DNA damage), and
analyzed by fluorescence microscopy. Error bars represent SD.
(TIF)
Figure S15 Analysis of E2F1, MYC, SP1 and p53 occupancy on
the TERT promoter in p53+ and p532 HCT116 cells. (A–D)
ChIP analysis in p53+ and p532 HCT116 cells monitoring
occupancy of E2F1 (A), MYC (B), SP1 (C) and p53 (D) at three
regions of the TERT promoter: in the first intron, or 300 bp or
3 kb upstream of the transcription start-site. Error bars represent
SD.
(TIF)
Figure S16 ATR kinase activity is not required for TERT
expression in human MCF10A cells expressing a dominant-
negative p53 mutant or in p532 mouse embryo fibroblasts. (A)
(Left) Immunoblot analysis monitoring TERT and ETV1 levels in
human MCF10A cells stably expressing a p53 dominant-negative
mutant (p53-DD), or the empty expression vector, treated in the
presence or absence of ETP46464. b-actin (ACTB) was monitored
as a loading control. (Right) Immunoblot analysis monitoring the
level of the p53 dominant-negative mutant in the MCF10A stable
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cell lines used in panel A. (B) Immunoblot analysis monitoring
TERT and ETV1 levels in p53+ and p532 mouse embryo
fibroblasts (MEFs) treated in the presence or absence of
ETP46464. a-tubulin (TUBA) was monitored as a loading control.
(TIF)
Table S1 List of 103 genes identified in the genome-wide RNAi
screen for genes preferentially required for proliferation of p532
human cancer cell lines.
(DOC)
Table S2 Summary of the cell culture results in Figure 1 and
Figure 2.
(DOC)
Table S3 Basis for the p532 status in each of the p532 cell lines
used in this study.
(DOC)
Table S4 Oligo ID numbers and locations for shRNAs obtained
from Open Biosystems, sequences of synthesized siRNAs, and
primer sequences for qRT-PCR analysis.
(DOC)
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